Novartis to pay nearly $178M in lawsuit over BRAF drug — and will be on the hook for royalty

Novartis to pay nearly $178M in lawsuit over BRAF drug — and will be on the hook for royalty

Source: 
Endpoints
snippet: 

After a four-year battle over a cancer drug patent, Novartis has been ordered by a California judge to pay a Daiichi Sankyo subsidiary $177.8 million.

Plexxikon filed a lawsuit against the pharma giant in 2017, alledging that Tafinlar, a rival to its melanoma drug Zelboraf that was brought to market in collaboration with Roche, has stepped on its intellectual property. The jury ruled in its favor, adding that the infringement is in fact willful.